Effect of StRess and ExeRcize on the Outcome After Chemo-Radiation
Launched by MAASTRICHT RADIATION ONCOLOGY · Jun 21, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how stress and exercise affect the outcomes of treatment for patients with glioblastoma (GBM), a serious and hard-to-treat brain tumor. Researchers want to understand if managing stress can improve how well patients respond to chemoradiation, a common treatment that combines chemotherapy and radiation therapy. They believe that stress hormones might impact how the body reacts to treatment and could even make it less effective.
To participate in this study, you should be between 65 and 74 years old, diagnosed with GBM, and eligible for a specific treatment plan called the Stupp regimen. You'll also need to wear a smartwatch during your treatment, which helps track your stress levels. The study is currently looking for participants, and everyone is welcome to join, regardless of gender. If you’re interested, you will be closely monitored to see how stress and exercise impact your treatment experience. This trial could help provide valuable insights that may benefit future patients with GBM.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients treated with Stupp or Elderly protocol: GBM WHO IV, astrocytoma WHO IV IDHmt, astrocytoma WHO II IDHwt (GBM-like).
- • willing to wear the smart watch during the treatment protocol
- Exclusion Criteria:
- • younger than 18 years
- • not in possession of a smart phone
About Maastricht Radiation Oncology
Maastricht Radiation Oncology is a leading clinical trial sponsor dedicated to advancing the field of radiotherapy through innovative research and development. Based in Maastricht, the Netherlands, the organization specializes in conducting high-quality clinical trials that aim to improve treatment outcomes for cancer patients. With a strong emphasis on collaboration and multidisciplinary approaches, Maastricht Radiation Oncology integrates cutting-edge technology and evidence-based methodologies to explore novel therapeutic strategies. Their commitment to patient-centered care and rigorous scientific standards positions them at the forefront of oncology research, driving progress in cancer treatment and management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Maastricht, Limburg, Netherlands
Patients applied
Trial Officials
Karen Zegers, PhD
Principal Investigator
Maastro Clinic, The Netherlands
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials